Merck Serono takes option on resurrected T cell therapy for MS
This article was originally published in Scrip
Executive Summary
Merck Serono has obtained an option from Opexa for $5 million for an exclusive license to develop and commercialize Tcelna (imilecleucel-T), a potential first-in-class personalized T cell therapy for patients suffering from multiple sclerosis (MS). With Opexa embarking on an expanded clinical program, this may represent the start of the resurrection for Tcelna, an agent that only a few years ago seemed clinically dead and buried.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.